{"classes":[{"categories":[{"measurements":[{"comment":"Data was not summarized since none of the participants had Ctrough values above lower limit of quantification (LLOQ).","groupId":"OG000","spread":"NA","value":"NA"}]}],"title":"Cycle 1 Day 1 (n=15)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"148","value":"298"}]}],"title":"Cycle 1 Day 15 (n=92)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"154","value":"293"}]}],"title":"Cycle 2 Day 1 (n=62)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"135","value":"306"}]}],"title":"Cycle 3 Day 1 (n=61)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"156","value":"291"}]}],"title":"Cycle 5 Day 1 (n=47)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"}],"units":"Participants"}],"description":"Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.","dispersionType":"Standard Deviation","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) analysis population included all randomized participants who received at least 1 dose of study treatment and had 1 of the PK parameters of interest. Here \"N\" (number of participants analyzed) signifies participants evaluable for this measure. n=participants evaluable at specific time points.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 3, 5","title":"Plasma Concentration of Crizotinib","type":"SECONDARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}